We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
-13.34%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$2.15B
AUM Growth
-$354M
Cap. Flow
+$252M
Cap. Flow %
11.69%
Top 10 Hldgs %
47.71%
Holding
76
New
9
Increased
16
Reduced
38
Closed
3

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$76.6M
2
XLRN
Acceleron Pharma
XLRN
+$64.1M
3
AGEN
Agenus
AGEN
+$39M
4
EIDX
Eidos Therapeutics, Inc. Common Stock
EIDX
+$30.8M
5
BEAM icon
Beam Therapeutics
BEAM
+$17.3M

Top Sells

Rank Stock Value
1
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$63.6M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$38.8M
3
CCXI
ChemoCentryx, Inc.
CCXI
+$37.2M
4
ASND icon
Ascendis Pharma A/S
ASND
+$19.5M
5
CRSP icon
CRISPR Therapeutics
CRSP
+$19.1M

Sector Composition

Rank Sector Weight
1 Healthcare 76.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BHVN
76
CALL
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
– –
-500,000
Closed -$27.2M
1 2 3
4

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.79% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return

Cormorant Asset Management's Q1 2020 Portfolio in Review

As of Q1 2020, Cormorant Asset Management held 76 positions worth $2.15B, down 14% from $2.51B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Cormorant Asset Management deployed $252M of net new capital in Q1 2020, opening 9 new positions and adding to 16 existing holdings. Its largest new stake was Revolution Medicines: 2,767,078 shares worth $60.6M.

By sector, the portfolio is most concentrated in Healthcare at 76% of assets, down from 84% a quarter earlier.

On the sell side, the largest reduction was Reata Pharmaceuticals, Inc. Class A Common Stock, an estimated $63.6M trimmed.

  • Cormorant Asset Management's largest Q1 2020 buy was Revolution Medicines: 2,767,078 shares worth $60.6M.
  • Cormorant Asset Management added most to Eidos Therapeutics, Inc. Common Stock in Q1 2020, an estimated $30.8M increase.
  • Cormorant Asset Management's biggest Q1 2020 reduction was Reata Pharmaceuticals, Inc. Class A Common Stock, cutting an estimated $63.6M.
  • Cormorant Asset Management fully exited Ra Pharmaceuticals, Inc. Common Stock in Q1 2020, selling an estimated $13.9M.
  • Cormorant Asset Management's ten largest holdings make up 48% of its $2.15B portfolio in Q1 2020.
  • Cormorant Asset Management opened 9 new positions and closed 3 in Q1 2020.
  • Cormorant Asset Management's portfolio value fell 14% quarter-over-quarter to $2.15B.

Based on Cormorant Asset Management's 13F filing for Q1 2020, filed 15 May 2020.